<DOC>
	<DOCNO>NCT02599129</DOCNO>
	<brief_summary>Alopecia areata medical condition , hair fall patch . The hair fall scalp elsewhere face body . Alopecia areata autoimmune skin disease , mean immune system recognize hair follicle foreign attack , cause round patch hair loss . It progress total scalp hair loss ( alopecia totalis ) complete body hair loss ( alopecia universalis ) . The scalp commonly affect area , beard hair-bearing site affect alone together scalp . Alopecia areata occur male female age , highly unpredictable condition tend recur . Alopecia areata cause significant distress patient family . Aim : To assess effect new treatment call secukinumab patient alopecia areata . A total 30 patient include study , run total 28 week .</brief_summary>
	<brief_title>A Study Secukinumab Treatment Alopecia Areata</brief_title>
	<detailed_description />
	<mesh_term>Alopecia</mesh_term>
	<mesh_term>Alopecia Areata</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Male female subject least 18 year age If female , subject pregnant nursing Subject able provide write informed consent comply requirement study protocol . Subjects woman childbearing potential must negative urine pregnancy test screening must practice adequate , medically acceptable method birth control least 30 day Day 0 least 6 month last study drug administration . Acceptable method birth control include intrauterine device ( IUD ) ; oral , transdermal , implanted inject hormonal contraceptive ( must initiate least 1 month enter study ) ; tubal ligation ; abstinence barrier method spermicide . Otherwise , childbearing potential , subject must : sterile vasectomized partner ; hysterectomy , bilateral oophorectomy clinically diagnose infertile ; menopausal state least year . Subject AA ( unequivocal case AA ) , affect least 60 % scalp , present least 6 month . Tuberculin purify protein derivative ( PPD ) QuantiFERON TBGold test ( QFT ) negative time screening , patient history positive PPD QuantiFERON , he/she complete appropriate prophylaxis . Subject judge good general health determine principal investigator base upon result medical history , laboratory profile , physical examination . Other concomitant type alopecia ( androgenetic , female pattern , traction , scar others ) Any subject pregnant refuse practice acceptable method birth control ( state inclusion criterion # 4 ) History ongoing , chronic recurrent infectious disease , evidence tuberculosis infection define positive tuberculin purify protein derivative ( PPD ) QuantiFERON TBGold test ( QFT ) screening . Subjects positive indeterminate PPD QFT test may participate study full tuberculosis work ( accord local practice/guidelines ) complete within 12 week prior randomization establishes conclusively subject evidence active tuberculosis . If presence latent tuberculosis establish , treatment must initiate least 4 week prior randomization course prophylaxis plan complete . Active Crohn 's disease Known hypersensitivity latex Subjects history HIV , history positive HCV HBV Previous exposure Secukinumab drug target IL17A receptor ; use sensitize therapy alopecia areata include DPCP , squaric acid , DNCB within 1 month ; PUVA , form phototherapy within 1 month ; use immunosuppressive therapy ( systemic corticosteroid , methotrexate , azathioprine , mycophenolate mofetil , cyclosporine ) within 1 month ; use topical therapy ( two week ) . All therapy allow study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Alopecia areata</keyword>
</DOC>